Share Price.com
Share Search

Motif Bio Share News


Share Price: 39.63   Bid / Ask: 0.00 / 0.00   High: 41.89   Low: 39.00



Motif Bio Plc Ord 1P Share News

Motif Bio presents wound treatment data at San Francisco conference


3 Oct '18
... Bio-pharmaceutical company Motif Bio said it would present data on its wound treatment at an industry conference in San Francisco.

The data for its iclaprim treatment would be presented at IDWeek from 4-7 of October.

The data showed that iclaprim was non-inferior to vancomycin Read More...

HeadlineDate
Motif Bio presents wound treatment data at San Francisco conference3 Oct '18
Motif Bio shareholder Amphion extends loan repayment by a year28 Sep '18
Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p25 Sep '18
Motif Bio losses narrow on lower R&D spend25 Sep '18
Motif Bio presents skin treatment study data at Lisbon conference5 Sep '18
Amphion Innovations cuts holding in Motif Bio to 8.5%21 Aug '18
Motif Bio to present antibiotic treatment data at Lisbon conference17 Aug '18
Motif Bio skin infection treatment accepted for filing by FDA14 Aug '18
Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1p16 Jul '18
Motif Bio says director Robert Bertoldi to resign3 Jul '18
Motif Bio completes rolling submission of NDA to the FDA for iclaprim14 Jun '18
Motif Bio presents skin infection treatment test results at Atlanta conference11 Jun '18
Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1p8 May '18
Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p13 Apr '18
Motif Bio losses deepen on higher staff remunerations costs10 Apr '18
Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p4 Apr '18
Motif Bio starts rolling submission to FDA skin infection treatment3 Apr '18
Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p20 Mar '18
Motif Bio delays new drug application to FDA for skin-infection treatment20 Mar '18
Motif Bio CFO resigns2 Feb '18
Motif Bio files US funding registration request19 Jan '18
Motif Bio CEO to present at summit5 Jan '18
Motif Bio secures $20m debt financing15 Nov '17
Motif Bio presents drug trial data6 Oct '17
Broker Forecast - Peel Hunt issues a broker note on Motif Bio Plc Ord 1p5 Oct '17
Potential energy cap hits Centrica and SSE4 Oct '17
Utility stocks and Shell weigh on FTSE4 Oct '17
Motif Bio losses increase29 Sep '17
Motif Bio to present at Rodman & Renshaw conference31 Aug '17
Broker Forecast - finnCap issues a broker note on Motif Bio Plc Ord 1p7 Jun '17
FTSE jogs higher on mixed bag ;resources prices fall2 Jun '17
Motif Bio proposes raising £19.4m in placing2 Jun '17
Miners slump on sharp drop in metals prices18 Apr '17
Motif Bio announces positive topline results18 Apr '17
Broker Forecast - finnCap issues a broker note on Motif Bio Plc Ord 1p4 Apr '17
Broker Forecast - Beaufort Securities issues a broker note on Motif Bio Plc Ord 1p1 Feb '17
MTFB's Phase 3 clinical trial finishes patient treatment31 Jan '17
Motif Bio appoints chief financial officer18 Jan '17
Broker Forecast - Northland Capital issues a broker note on Motif Bio Plc Ord 1p14 Dec '16
Motif Bio updates on Revive-1 Phase 3 clinical trial8 Sep '16
Broker Forecast - Beaufort Securities issues a broker note on Motif Bio Plc Ord 1p17 Aug '16
Motif Bio widens H1 pretax loss16 Aug '16
Motif Bio defers US proposed US public offering9 Aug '16
Amphion partner Motif Bio to list on NASDAQ13 Jul '16
Motif Bio files for proposed US public offering13 Jul '16
Motif Bio resolutions passed at AGM2 Jun '16
Motif Bio materially widens FY pretax loss20 Apr '16
MTFB says first patient dosed in iclaprim in Phase 3 2 Mar '16
MTFB says Iclaprim clinical trial supplies made15 Dec '15
Motif Bio to present at Biotech Showcase7 Dec '15
Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News



SharePrice.com will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.